Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US
Authors:
- 25 March 2023
- journal article
- research article
- Published by Springer Nature in Therapeutic Innovation & Regulatory Science
- Vol. 57 (4) , 671-677
Abstract
Background Drug lag in Japan has greatly decreased over the past decades; however, new instances of drug lag have appeared along with changes in the circumstances of oncology drug development. We aimed to investigate the factors associated with the approval lag for new oncology drugs between Japan and the United States (US) over the past decade by comparing approval dates and modalities, lead indications, approval types, and phase I strategies for earlier approval in Japan. Method We descriptively evaluated the characteristics of 117 new oncology drugs approved in either Japan or the US from January 1, 2011, to December 31, 2020. Results Seventy-one drugs were approved in Japan, 112 in the US, five only in Japan, and 46 only in the US. Interestingly, new oncology drugs were predominantly developed by the top 20 pharmaceutical companies in Japan; however, the opposite was true for drugs that were not yet approved in Japan. However, no clear trend was observed in the relationship between drug lag and the studied factors, except for the phase I strategy. There was a numerical but clear trend in which a higher percentage of phase I multiregional clinical trials (MRCTs) in the drug development strategy was observed for drugs with earlier approval in Japan. Conclusion Participation in global drug development during the early stages, such as during phase I MRCTs, is one of the keys to successfully minimizing this new instance of drug lag in Japan.Keywords
This publication has 29 references indexed in Scilit:
- Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including JapanClinical Therapeutics, 2018
- Utilization of the Bridging Strategy for the Development of New Drugs in Oncology to Avoid Drug LagThe Journal of Clinical Pharmacology, 2017
- Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodiesAnnals of Oncology, 2016
- The Relationship Between Development Start Lag and Approval Lag in Oncology Drug Development in JapanTherapeutic Innovation & Regulatory Science, 2015
- Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?International Journal of Clinical Oncology, 2015
- Relationship between drug lag and factors associated with clinical trials in JapanJournal of Clinical Pharmacy and Therapeutics, 2014
- Recent Trends and Success Factors in Reducing the Lag Time to Approval of New Drugs in JapanClinical Pharmacology & Therapeutics, 2014
- Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer DrugsClinical Cancer Research, 2014
- Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in JapanClinical Pharmacology & Therapeutics, 2013
- Delays in New Drug Applications in Japan and Industrial R&D StrategiesClinical Pharmacology & Therapeutics, 2009